Central Precocious Puberty (CPP) Treatment: What to Expect

Central Precocious Puberty (CPP) is early activation of hypothalamic-pituitary-gonadal axis (<8 years girls, <9 years boys). Treatment with GnRH agonists (leuprolide, histrelin, triptorelin) halts progression.

Physical Changes During Treatment

  • Growth: Initial growth spurt slows; adult height potential preserved (key goal).
  • Girls: Breast regression/softening; menses stop. Vaginal discharge decreases.
  • Boys: Testicular volume stabilizes/decreases; penile growth halts; pubic hair thins.
  • Skin: Acne, body odor improve.

Emotional & Social Aspects

  • Relief from peer mismatch, teasing, early sexualization.
  • Mood swings may persist (hormonal fluctuations, psychosocial stress).
  • Counseling/support groups beneficial.

Treatment Logistics

  • Formulations: Monthly IM injection (leuprolide), 3-month depot, 6-month implant (histrelin), daily nasal spray (nafarelin).
  • Monitoring: q3–6mo: height velocity, bone age, hormone levels (LH, estradiol/testosterone), injection site reaction.
  • Bone Health: Calcium/vitamin D, weight-bearing exercise. DXA if prolonged treatment.

Discontinuation

  • Typically at age 11 (girls) / 12 (boys) – bone age ~12/13.
  • Puberty resumes spontaneously within months.
  • Fertility preserved.

Family Support

  • Age-appropriate explanation: "Medicine pauses growing up too fast."
  • Validate feelings; involve child in decisions.
  • Coordinate with school for privacy (injections, bathroom needs).

CPP treatment is highly effective. Multidisciplinary team (endocrine, psychology, nursing) optimizes physical and emotional outcomes.

Brain & Nervous System - Related Articles